The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2018 | Value and cost in MM treatment
Multiple myeloma (MM) is an expensive cancer to treat, with costly drugs that are often used in combination. In this video, recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL, Vincent Rajkumar, MD, of the Mayo Clinic, Rochester, MN, discusses why this treatment is so expensive, and how to combat this problem. He gives an overview of the reasons behind extortionate drug prices, including some issues specific to the USA, such as the fact that Medicare cannot negotiate drug prices and there is no value-based pricing system. He suggests how these issues can be resolved with legislatory changes, which would introduce value-based pricing, and the potential to import drugs for personal use.
